Verona Pharma plc

Verona Pharma — Merger or Acquisition (September 2025)

17 slides from Verona Pharma's merger presentation, Sep 10, 2025

  1. Slide 1: Verona Pharma Employee Town Hall with Merck

    Verona Pharma Employee Town Hall with Merck Friday, September 5, 2025

  2. Slide 2: Forward-looking statement of Merck & Co., Inc.

    Forward-looking statement of Merck & Co., Inc. This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upo

  3. Slide 3: Additional information and where to find it

    Additional information and where to find it In connection with the proposed transaction between Verona Pharma and Merck, Verona Pharma will file with the Securities and Exchange Commission (“SEC”) a proxy statement on Schedule 14A. Additionally, Verona Pharma may file other relevant materials with t

  4. Slide 4: Participants in the solicitation

    Participants in the solicitation Verona Pharma, Merck and certain of their directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of Verona Pharma in connection with the proposed transaction. Information about Verona Pharma’s directors

  5. Slide 5: Welcome

    5 Welcome Susan Neunaber Executive Director, Business Development​ Merck Integration Office

  6. Slide 6: Today's agenda

    1 Today’s agenda 6 Welcome 2 Executive message 3 Our commitment to you 4 What to expect next

  7. Slide 7: Executive message

    7 Executive message Jeff Simmons Chief of Staff, Chairman of the Board & CEO

  8. Slide 8: Our commitment to you

    8 Our commitment to you Carl Segerstrom SVP, Human Health HR

  9. Slide 9: Our opportunity to bring together two science-driven companies

    This is our opportunity to bring together two science-driven companies, combining Verona’s strong early launch success with Merck’s large commercial footprint and strengthening Merck’s growing cardio-pulmonary portfolio. We are looking forward to working with you We need your partnership, experience

  10. Slide 10: Our retention approach

    *If an employee resigns or is terminated for Cause during the Retention Period, no Retention amount or Severance package will be paid. Retention Period Your retention agreement states the duration of your retention period post Close. Retention Bonus The value of your retention bonus and other terms

  11. Slide 11: Verona's Change in Control Severance Plan

    After completing the requested knowledge transfer and provided you are not terminated for “cause” as defined in the Verona Employee Change in Control Severance Plan, you will be eligible for a severance package. 11 Verona’s Change in Control Severance Plan *Outplacement through severance period or u

  12. Slide 12: What you can expect after close

    Integration is the date after the Close when you will transition onto Our Company payroll administration, benefits, and programs & policies. Integration Timing: April 1, 2026 Your current day-to-day work will generally not change; however, over time you will be asked to participate in certain activi

  13. Slide 13: Next steps with HR

    13 Review materials you’re received so far such as your retention agreement, email pertaining to Verona 401(k) and the Employee Resource Guide. Continue to leverage your Verona team for all HR related questions. We are partnering closely with them to get you the information you need Next steps with

  14. Slide 14: Frequently asked questions

    Frequently asked questions Let’s go through answers to common queries. 14

  15. Slide 15: Frequently asked questions on retention agreements

    For more information on these topics, review the Employee Resource Guide provided to you with your Retention Agreement. We will continue to update the Frequently Asked Questions guide as we receive additional questions. What happens if I do not sign my retention agreement? If you choose not to sign

  16. Slide 16: What to expect next

    16 What to expect next Susan Neunaber Executive Director, Business Development​ Merck Integration Office

  17. Slide 17: Thank you!

    Thank you!

Verona Pharma — Merger or Acquisition (September 2025) on 6ix